opdualag
bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanoma - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.
cabometyx
ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastiski līdzekļi - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.
bsn finish first® n.o.- xplode™ (2017.) pulveris
bioshell teoranta - pulveris
soluro od first choice (2016.) kapsula
ražots es pēc sia "solepharm pharmaceuticals" pasūtījuma - kapsula
nannycare® first infant milk pulveris
partnerlink, sia - pulveris
nannycare® first infant milk pulveris
partnerlink, sia 40003958698 pļavnieku iela 9-22, rīga, lv-1021, latvija - pulveris - cits - mākslīgais piena maisījums zīdaiņiem
bsn finish first® nitrix® 2.0 (2017.) tablete
bioshell teoranta - tablete
nannycare® first infant milk pulveris
partnerlink, sia - pulveris
olimp® sport nutrition vita-min one your first sports vitamins (2024.) kapsula
kapsula
activlab® lift your world world’s first bcaa-glu bcaa xtra instant (2024.) pulveris
pulveris